Company History – Key Milestones
2000 David Masters, Ph.D., a biochemist and biomaterials expert with credentials from Rutgers and Harvard leaves his position at the Mayo Clinic in Rochester, Minnesota to launch Gel-Del Technologies, Inc. in St. Paul, Minnesota. Initial seed funding is provided by a grant from the National Institutes of Health to facilitate the development of biomaterials that deliver local anesthetics to create nerve block in the treatment of chronic pain.
2002 The US Patent and Trademark Office allows the Company’s first patent related to its biomaterials and long-term drug delivery systems. US 6,342,250 – Drug Delivery Devices Comprising Biodegradable Protein for the Controlled Release of Pharmacologically Active Agents & Method of Making the Drug Delivery Devices.
2002 The Company finalizes a royalty-free technology transfer from the Mayo Clinic.
2003 The National Institutes of Health awards the company a Phase I grant in the amount of $150K. This grant titled “Arterial-Mimetic Grafts Molded from Purified Proteins” provides initial validation that the Company’s vascular graft technologies have significant advantages over the current grafts in clinical use.
2003 The Company is awarded the Tekne Award, in the Biotechnology category, from the Minnesota High Tech Association and Minnesota Technology, Inc., in partnership with Medical Alley, MNBIO and Minnesota Project Innovation. The Tekne awards recognize companies and individuals who have shown superior technology innovation and leadership in Minnesota.
2004 The Company’s Series A financing round secures $1.5M in funding.
2004 The Company discovers, develops and submits patent applications on its novel scalable biomatrix material, biomaterial uses and manufacturing processes that utilize complex coacervation to create a protein based biomaterial with thermoplastic and regenerative properties.
2005 The National Institutes of Health awards the Company a $2.1M Phase II grant. The two-year project, titled “Arterial-Mimetic Grafts Molded from Purified Proteins,” completes the pre-clinical testing required for a Food and Drug Administration (FDA) vascular graft clinical trial.
2006 The Food and Drug Administration conditionally approve the Company’s Investigational Device Exemption (IDE) to conduct a Randomized, Double Blind, and Multicenter Dermal Filler Clinical Trial.
2006 The Company’s Series B financing round secures $800K in funding.
2007 The Primary Efficacy Endpoint is met in the successful Dermal Filler Clinical Trial that includes six study sites and 150 subjects.
2007 The Company’s Series C financing round secures $775K in funding.
2008 Dr. Masters is an invited speaker at the 2008 Annual Meeting of the Association of Pharmaceutical Scientists regarding the successful use of our drug delivery devices for vascular repair. The presentation is titled “Drug-Eluting Elastin-Collagen-Heparin Matrix (ECM Material) for Anastomosis Site Repair in Porcine Arterial Graft Studies.”
2008 Stacy Smith, M.D. presents the results of our successful dermal filler clinical trial at the American Society for Dermatology Surgery Conference. The presentation is titled “A Comparison Study of a Novel Dermal Filling Agent Based Upon a Collagen and Elastin Matrix Compared to an Approved Hyaluronic Acid Dermal Filler.”
2009 As an invited speaker, Dr. Masters presents at the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference about the advantages of our vascular shunts for limb salvage and repair. The presentation is titled “VasoGraft™: Regenerative, Small Diameter Blood Vessel Graft to Save Lives and Limbs.”
2009 Dr. Robert Hale of the Institute of Surgical Research (ISR), San Antonio Military Medical Center invites Dr. Masters to present to the entire faculty of the Institute of Surgical Research. The presentation is titled “Protein-Matrix Particle Scaffolding for Non-Scarring Skin Repair and Dermis Regeneration for Maxillofacial Trauma.”
2010 The company enters into a Special Purpose Cooperative Research & Development Agreement with the 59th Medical Wing at the Lackland Air Force Base in San Antonio, Texas where we successfully demonstrate the effectiveness of our Trauma-Specific Vascular Injury Shunt to help save the severed limbs of warfighters.
2010 The US Patent and Trademark Office allows the Company’s second US Patent 7,662,409 titled “Protein Matrix Materials, Devices and Methods of Making and Using Thereof”, which was originally filed in 2001; this patent protects the Company’s compression based biomatrix materials.
2011 The National Institutes of Health awards the Company a $1.3M Phase II Continuation Grant titled “Arterial-Mimetic Grafts Molded from Purified Proteins.” This grant completes the pre-clinical studies for an improved vascular shunt graft that is often required for dialysis patients.
2011 The National Institutes of Health awards the Company a $250K Grant titled
“Non-Clotting Micro-Catheters for Newborns.” The work demonstrates the effectiveness of the Company’s biomaterial coating to improve all types of indwelling vein catheters including pediatric micro-catheters.
2012 The US Patent and Trademark Office allows the Company’s third US Patent 8,153,591 titled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof”. This key patent, which was filed in 2004, includes ninety-three claims focused on many aspects of our biomatrix materials, biomaterial uses and manufacturing processes, which include a complex coacervation process.
2012 Dr. Masters is invited by Dr. Robert Tranquillo to speak at the Engineered Tissues Session of the Design of Medical Devices Conference at the University of Minnesota. The presentation is titled “Biomimetic Extracellular Matrix using Purified Collagen, Elastin and Heparin: Vascular Scaffolding” (the session includes a talk by Christopher Breuer, Yale School of Medicine: Next Generation Tissue Engineered Vascular Grafts).
2013 The US Patent and Trademark Office allows two of the Company’s Patents, US Patent 8,465,537 titled “Encapsulated or Coated Stent Systems” and US Patent 8,529,939 titled “Mucoadhesive Drug Delivery Devices and Methods of Making and Using Thereof.”
2013 Dr. Masters is an invited speaker at the Annual Meeting of the Society of Biomaterials. The presentation is titled “Clinically Translated, Thermoplastic Biomaterial as Absorbable Scaffold for Functional Regeneration of Vascular, Dermal and Other Tissues: Biocoacervation of Purified Extracellular Matrix (ECM) Protein and Glycosaminoglycan.”
2014 Gel-Del signs a licensing and distribution agreement with PetVivo for commercialization of our osteoarthritis and lameness device in the animal healthcare sector.
2014 The US Patent and Trademark Office allows US Patent 8,623,393 titled “Biomatrix Structural Containment and Fixation Systems and Methods of Use Thereof” to secure technology related the use of our biomatrix materials to repair non-union or delayed-union bone fractures.
2014 The US Patent and Trademark Office allows US Patent 8,871,267 titled “Protein Matrix Materials, Devices and Methods of Making and Using Thereof”, which has 38 patent claims and is a continuation of or our previously issued Patent US 7,662,409 of the same title.
2015 The US Patent and Trademark Office allows US Patent 9,107,937 titled “Wound Treatments with Cross-linked Protein Amorphous Biomaterials.” This continuation of US Patent 8,153,591 adds additional claims focused on wound care treatment using our coacervation based biomaterials and drug delivery devices.
2015 Gel-Del Technologies and PetVivo Holdings agree to terms involving a security exchange, thereby merging the two entities.
2017 Dr. Masters is invited to speak on the effectiveness of our particles as an osteoarthritis treatment at the Society for Biomaterials Annual Meeting. The presentation is titled “Particles for Osteoarthritis Treatment: Injected Wet Particulate of Collagen-Elastin-Glycosaminoglycan Matrix into Synovial Fluid Mechanically Cushion Joint with Long Duration.” To recognize significant advances in the field Dr. Masters is awarded the Star Award for his abstract with the same title.
2017 Gel-Del Technologies & PetVivo Holdings complete the merger of the two entities. Gel-Del remains as a wholly owned subsidiary of PetVivo.
2017 The Company leases a new company headquarters and manufacturing facility in Edina, a suburb of Minneapolis, Minnesota. The new location expands the company’s production and office space requirements for veterinary product commercialization.